The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.
AMRI is offering its impurity solutions as a stand-alone service in response to new regulatory requirements that set limits for the amounts of elemental impurities in drug products.
The Carlyle Group and GTCR LLC are poised to complete the takeover of Albany Molecular Research (AMRI) after the early termination of the mandatory waiting period that covers such deals in the US.
AMRI has been hired by the NIH to provide synthesis and manufacturing services for APIs being developed by the National Center for Advancing Translational Sciences (NCATS) division of preclinical innovation.
Steroid API firm Gadea Pharmaceuticals helped AMRI grow revenue in the second quarter offsetting flat royalties and the impact of the closure of its site in Holywell, Wales.
As a dedicated Chemical Biology Consortium center, AMRI will provide a variety of drug discovery services to help advance early stage drug discovery projects.
With contract revenue growth of nearly 40%, CDMO (contract development and manufacturing organization) AMRI is seeing its acquisitions of OsoBio, two Aptuit facilities and a UK aseptic facility pay off.
Following its three acquisitions over the last year, AMRI is now looking to extend its footprint into India further with the acquisition of a FDA-approved API site, William Marth, president and CEO of AMRI, told attendees at the Barclays Global Healthcare...
AMRI has announced plans to close an API development and manufacturing plant in Wales, UK, after efforts to establish it as a conduit between the US and Europe were deemed unsuccessful.
CMO (contract manufacturing organization) AMRI has agreed to acquire Oso Biopharmaceuticals Manufacturing for $110m in cash and thereby expand to late-stage and commercial product manufacturing.
AMRI will acquire Cedarburg Pharmaceuticals for $38.2m (€27.7) in cash, plus $2.8m of assumed liabilities, to expand its API and drug development offerings.
Albany Molecular Research's (AMRI) stock fell more than 10% on Monday after announcing in an SEC filing that it was informed by its partner Bristol-Myers Squibb that it would terminate the development of an investigational depression drug.
Large scale manufacturing contract revenue in the first quarter of 2013 increased 14% over the same quarter in 2012 as AMRI (Albany Medical Research Inc.) saw an 11% increase in overall revenue.
Contract manufacturing organisations (CMOs) have been busy in the past week, with OsoBio expanding its plant and AMRI adopting a new relationship strategy.
AMRI says the US FDA has no concerns about its sterile fill-finish facility in Burlington, Massachusetts and that the challenge now is to win back customers.
Recapturing customers will not be easy for Albany Molecular Research (AMRI) after the problems at its manufacturing plant in Burlington, Massachusetts according to an analyst.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Parexel, Catalent, AMRI, BioStorage and BRANY.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at AMRI, Oracle, Cmed, BioClinica and BioStorage.
AMRI recorded a $6.0m (€4.6m) operating loss in the second quarter as restructuring charges and the lack of milestone payments offset contract service gains.
AMRI’s adjusted income from operations plummeted by 97 per cent in Q2 as a result of lower demand for contract services, in particular development and small scale manufacture.
Outsourcing-Pharma provides its latest round up of movements in the pharmaceutical outsourcing sector, including changes to AMRI’s leadership in India and a new VP at Covance.
Albany Molecular Research Inc (AMRI) faced a “challenging headwind” as 2008 drew to a close but still managed to boost its revenues by 19 per cent to $56.4m in the fourth quarter of 2008.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...
AMRI witnessed strong growth in two of its contract business during
the first quarter of 2008 although profit was impacted by its
dominant large-scale division, which lagged during the period.
Albany Molecular Research Inc (AMRI) recently turned in Q3 results,
posting figures buoyed by continued demand for its pharmaceutical
development services.
Albany Molecular Research (AMRI) has followed up its push into new
markets for its drug discovery operations by tapping into the
well-established trend for sourcing contract pharmaceutical
manufacturing from the lower-cost Asian region.
